gdc
ImmunotherapyLung Cancer

Immune Checkpoint Inhibitors Offer New Hope for Patients with Lung Cancer

Several immune checkpoint inhibitors are now approved for patients with non–small-cell lung cancer, giving hope to patients living with this disease.
November 2018 Volume 4 – Lung Cancer
Jane Morgan

Lung cancer remains the leading cause of cancer-related deaths in men and women, accounting for 1 in every 4 deaths caused by cancer in the United States. However, recent advances in immunotherapy, especially those called “immune checkpoint inhibitors,” bring new hope for patients with lung cancer.

Recommended For You
Immunotherapy
Why Target the Immune System?
By Colleen H. Erb, MSN, CRNP, ACNP-BC, AOCNP
The immune system attacks foreign substances by making large numbers of antibodies. These are proteins that attach to a specific protein on the cell called an antigen.
Lung Cancer
Being Your Own Advocate: A Mother’s Journey with ALK-Positive Lung Cancer
By Fatima Scipione
Laura Greco, a mother of 4, was shocked when a CT scan done after a car accident revealed that she had stage III non–small-cell lung cancer with ALK mutation. Now she works as a patient advocate to fight the stigma linked to lung cancer, which often results in late diagnosis and worse outcomes.
ImmunotherapyMultiple Myeloma
How CAR T-Cell Therapy Gave Cherie Rineker Her Life Back
By Kelsey Moroz
Chemotherapy for multiple myeloma had kept Cherie Rineker alive for 5 years, but then she realized she was slowly dying. So she embarked on a search for a clinical trial and by luck was able to join one. To her amazement, “What 2 stem-cell transplants and 13 other treatments had not been able to do in more than 65 months, CAR T-cell therapy did in less than 1 month,” she said.
Last modified: January 4, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country